Steven Robinette

This inventor holds 11 USPTO granted patents and 12 published patent applications and 1 EPO patent. Top assignees: Korro Bio, Inc., Disc Medicine, Inc., Abbvie Deutschland Gmbh & Co. Kg. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven Robinette. Retrieved from https://idiyas.com/inventor/steven-robinette

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 12)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 10)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

Abbvie Deutschland Gmbh & Co. Kg

patent

4. 1 out of 167

Abbvie Deutschland Gmbh and Co Kg

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715917 - METHODS OF USING ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS (2026-08-25),

2. 12715916 - ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS (2026-08-25),

3. 12655210 - ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING ANEMIA OF CHRONIC DISEASE (2026-06-16),

4. 12497452 - ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS (2025-12-16),

5. 12448620 - RNA-editing oligonucleotides and uses thereof (2025-10-21),

6. 12365729 - Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis (2025-07-22),

7. 12173285 - RNA-editing oligonucleotides and uses thereof (2024-12-24),

8. 12152050 - RNA-editing oligonucleotides and uses thereof (2024-11-26),

9. 12031131 - RNA-editing oligonucleotides and uses thereof (2024-07-09),

10. 11479575 - RNA-editing oligonucleotides and uses thereof (2022-10-25),

11. 11453878 - RNA-editing oligonucleotides and uses thereof (2022-09-27),

Title: The Innovative Work of Steven Robinette: Pioneering RNA-Editing Oligonucleotides

Introduction:

Steven Robinette, based in Fremont, NH, is a trailblazing inventor making significant contributions in the field of RNA-editing oligonucleotides. With a total of two patents under his name, Robinette exemplifies dedication and expertise in cutting-edge therapeutic solutions.

Latest Patents:

Robinette's latest patents include groundbreaking inventions in the realm of RNA-editing oligonucleotides. His pioneering work focuses on developing compositions and methods to treat disorders through deamination of adenosine in mRNA, thereby offering therapeutic benefits to individuals in need.

Career Highlights:

Currently associated with Korro Bio, Inc., Robinette plays a pivotal role in shaping innovative solutions within the biotechnology landscape. His relentless pursuit of scientific excellence and problem-solving skills reflect in his patented inventions that hold immense promise for the medical field.

Collaborations:

In his professional journey, Robinette collaborates closely with accomplished peers such as Andrew W Fraley and Nessan Anthony Bermingham. Together, they form a dynamic team driving forward the boundaries of RNA-editing technology and its potential applications in healthcare.

Conclusion:

Steven Robinette's remarkable work stands as a testament to his visionary approach and commitment to advancing medical science through innovative technologies. With a focus on RNA-editing oligonucleotides, Robinette's patents pave the way for transformative treatments and hold the promise of improving lives worldwide.

Profile summary based on public USPTO records.